{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:17Z","timestamp":1790701637624,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.retram.2026.103591","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:29:57Z","timestamp":1778891397000},"page":"103591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Donor demographics and leukopak consistency: Yield and composition as operational benchmarks for cell-therapy starting materials"],"prefix":"10.1016","volume":"74","author":[{"given":"Irene","family":"G\u00f3mez-Gr\u00e0cia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonnermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Paschold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Castey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Marie","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Renate","family":"Winterstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Wahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Gloger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liane","family":"Klinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Ingrid","family":"Baumann-Baretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9499-9895","authenticated-orcid":false,"given":"Francisco Javier","family":"Belda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.retram.2026.103591_bib0001","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001608","article-title":"Off-the-shelf\u2019 allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies","volume":"9","author":"Sinha","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2026.103591_bib0003","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/jpids\/piad077","article-title":"Virus-specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation","volume":"13","author":"Green","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.retram.2026.103591_bib0004","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.retram.2026.103591_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"issue":"14","key":"10.1016\/j.retram.2026.103591_bib0008","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic CAR T cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase 1 experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0009","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2025.150897","article-title":"Identifying modifiers of CAR T-cell therapeutic efficacy and safety: a systematic review and individual patient data meta-analysis","volume":"39","author":"Lalu","year":"2025","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.retram.2026.103591_bib0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt1395","article-title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","volume":"26","author":"Zakrzewski","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0012","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0013","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1537-2995.1971.tb04383.x","article-title":"Leukocyte and platelet collection from normal donors with the continuous flow blood cell separator","volume":"11","author":"Graw","year":"1971","journal-title":"Transfusion"},{"key":"10.1016\/j.retram.2026.103591_bib0014","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jim.2014.05.019","article-title":"Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs","volume":"409","author":"Garcia","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.retram.2026.103591_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0016","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0017","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable Manufacturing of CAR T cells for Cancer Immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"10.1016\/j.retram.2026.103591_bib0018","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.3390\/cancers13184664","article-title":"Urbano-Ispizua \u00c1. el al. CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies?","volume":"13","author":"Bartol\u00f3-Ibars","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-022-00359-3","article-title":"Donor T cells for CAR T cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/trf.15178","article-title":"Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies","volume":"59","author":"Tuazon","year":"2019","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0021","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0022","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0023","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with Relapsed\/Refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0024","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00113-018-0489-4","article-title":"[The new hemotherapy guideline]","volume":"121","author":"Strasser","year":"2018","journal-title":"Unfallchirurg"},{"issue":"8","key":"10.1016\/j.retram.2026.103591_bib0025","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2022.05.002","article-title":"Recommendations for procurement of starting materials by apheresis for advanced therapy medicinal products","volume":"24","author":"Manson","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.retram.2026.103591_bib0026","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.galenos.2023.2022.0534","article-title":"TCR-NK Cells: a Novel Source for Adoptive Immunotherapy of Cancer","volume":"40","author":"Karahan","year":"2023","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.retram.2026.103591_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer Therapy With TCR-Engineered T Cells: current Strategies, Challenges, and Prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0029","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/trf.15186","article-title":"Evaluation of peripheral blood mononuclear cell collection by leukapheresis","volume":"59","author":"Chen","year":"2019","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.retram.2026.103591_bib0030","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1704034","article-title":"Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis","volume":"31","author":"Sarkodee-Adoo","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.retram.2026.103591_bib0031","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s40883-019-00124-3","article-title":"The challenge of variability in chimeric antigen receptor T cell manufacturing","volume":"6","author":"Fesnak","year":"2020","journal-title":"Regen Eng Transl Med"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0032","first-page":"285","article-title":"Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany","volume":"22","author":"Wagner","year":"1995","journal-title":"Infusionsther Transfusionsmed"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000490859","article-title":"Low-Volume Leukapheresis in Non-Cytokine-Stimulated Donors for the Collection of Mononuclear Cells","volume":"45","author":"Anyanwu","year":"2018","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0034","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000528331","article-title":"Get Off on the Right Foot: how to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing","volume":"50","author":"Pi\u00f1eyroa","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"3","key":"10.1016\/j.retram.2026.103591_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bmt.1704781","article-title":"Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?","volume":"35","author":"Gidron","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0036","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0973-6247.164273","article-title":"Autologous peripheral blood stem cell harvest: collection efficiency and factors affecting it","volume":"10","author":"Tiwari","year":"2016","journal-title":"Asian J Transfus Sci"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0037","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/trf.12506","article-title":"Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems","volume":"54","author":"Schulz","year":"2014","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0038","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/trf.16856","article-title":"Low hematocrit reduces the efficiency of CD34+ cell collection when using the Spectra Optia continuous mononuclear cell collection procedure","volume":"62","author":"Kondo","year":"2022","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.retram.2026.103591_bib0039","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/trf.17765","article-title":"Collection efficiency and safety of large-volume leukapheresis for the manufacturing of tisagenlecleucel","volume":"64","author":"Kitamura","year":"2024","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0040","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminhematol.2020.07.005","article-title":"Improving CAR T cell therapy by optimizing critical quality attributes","volume":"57","author":"Reddy","year":"2020","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0043","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/vox.12540","article-title":"Evolution of MNC and lymphocyte collection settings employing different Spectra Optia(\u00ae) Leukapheresis systems","volume":"112","author":"Punzel","year":"2017","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.retram.2026.103591_bib0044","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1381\/096089206776116453","article-title":"Obesity and the white blood cell count: changes with sustained weight loss","volume":"16","author":"Dixon","year":"2006","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clim.2005.03.020","article-title":"Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults\u2013a monocentric German study","volume":"116","author":"Jentsch-Ullrich","year":"2005","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0046","first-page":"499","article-title":"An Italian national multicenter study for the definition of reference ranges for normal values of peripheral blood lymphocyte subsets in healthy adults","volume":"84","author":"Santagostino","year":"1999","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.retram.2026.103591_bib0047","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","article-title":"Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland","volume":"72","author":"Bisset","year":"2004","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23589-9","article-title":"T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy","volume":"12","author":"Wada","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.retram.2026.103591_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006624","article-title":"Imbalance in the game of T cells: what can the CD4\/CD8 T-cell ratio tell us about HIV and health?","volume":"13","author":"McBride","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.retram.2026.103591_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0051","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.retram.2026.103591_bib0052","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.retram.2026.103591_bib0053","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1038\/s41375-021-01348-5","article-title":"Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry","volume":"35","author":"Schultze-Florey","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.retram.2026.103591_bib0054","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1016\/j.celrep.2018.05.057","article-title":"Age-related decline in primary CD8(+) T cell responses is associated with the development of senescence in virtual memory CD8(+) T cells","volume":"23","author":"Quinn","year":"2018","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.retram.2026.103591_bib0055","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V92.7.2410","article-title":"Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells","volume":"92","author":"Rukavina","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2026.103591_bib0056","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10522-008-9138-6","article-title":"The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age","volume":"9","author":"Wikby","year":"2008","journal-title":"Biogerontology"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0057","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103591_bib0058","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1086\/419555","article-title":"Seasonal changes in immune function","volume":"71","author":"Nelson","year":"1996","journal-title":"Q Rev Biol"},{"issue":"1","key":"10.1016\/j.retram.2026.103591_bib0059","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/trf.12238","article-title":"Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor","volume":"54","author":"Chen","year":"2014","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.retram.2026.103591_bib0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/PL00007585","article-title":"Lymphocyte subsets in peripheral blood and smoking habits","volume":"175","author":"Schaberg","year":"1997","journal-title":"Lung"},{"issue":"10","key":"10.1016\/j.retram.2026.103591_bib0061","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.retram.2026.103591_bib0062","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cellimm.2011.10.009","article-title":"Gender effect on in vitro lymphocyte subset levels of healthy individuals","volume":"272","author":"Abdullah","year":"2012","journal-title":"Cell Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103591_bib0063","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000337051","article-title":"Influence of age, gender and lifestyle in lymphocyte subsets: report from the Spanish Gait-2 Study","volume":"127","author":"Garc\u00eda-Dabrio","year":"2012","journal-title":"Acta Haematol"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:31:18Z","timestamp":1790699478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452318626000279"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103591","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor demographics and leukopak consistency: Yield and composition as operational benchmarks for cell-therapy starting materials","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103591"}}